Review article
Human protein C concentrate in pediatric septic patients
GIOVANNI LANDONI
orcid.org/0000-0002-8594-5980
; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
GIACOMO MONTI
; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
ALBERTO FACCHINI
; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
FRANCESCO CAMA
; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
ELENA BIGNAMI
; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
LUCA CABRINI
; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
FEDERICO PAPPALARDO
; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
ALBERTO ZANGRILLO
; Department of Anesthesia and Intensive Care; Universita Vita-Salute San Raffaele Milano; V. Olgettina 60; Milano; Italy
Abstract
Severe sepsis and septic shock are leading causes of morbidity and mortality in the pediatric population. Unlike what is suggested for the adult population, recombinant human activated protein C (rhAPC) is contraindicated in children. Long before rhAPC was considered for use in pediatric patients, case reports appeared on the safe administration of protein C zymogen. Therefore, we conducted a systemic review of currently available data on protein C zymogen (PC) use among children affected by severe sepsis or septic shock.
A total number of 13 case series or case reports and a dose-finding study were found on the use of PC in the pediatric intensive care unit, reporting on 118 treated children, with an overall survival of 84%. There was no bleeding complication, the only reported complication being a single mild allergic reaction. These studies show that PC is safe, not associated with bleeding and possibly useful for improving coagulation abnormalities of sepsis.
Keywords
sepsis; pediatric; protein C; drug therapy; review
Hrčak ID:
51529
URI
Publication date:
1.4.2010.
Visits: 1.376 *